Ten year follow‐up of high‐risk patients treated during the early experience with transcatheter aortic valve replacement

2020 ◽  
Author(s):  
Janarthanan Sathananthan ◽  
Sandra Lauck ◽  
Jopie Polderman ◽  
Maggie Yu ◽  
Anna Stephenson ◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Early Experience ◽  
High Risk Patients ◽  
Transcatheter Aortic Valve ◽  
Risk Patients

scholarly journals One-year Outcome after Transcatheter Aortic Valve Replacement for Aortic Regurgitation: A Single-Center Study

2021 ◽  
Author(s):  
Lulu Liu ◽  
Xiaoling Yao ◽  
Ying Peng ◽  
Weina Huang ◽  
Jun Shi ◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Aortic Regurgitation ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Stroke Incidence ◽  
High Risk Patients ◽  
Transcatheter Aortic Valve ◽  
Risk Patients

Background: Presently, there are limited reports in the literature on the post-operative (mid-term) clinical outcome for pure Aortic Regurgitation (AR) following Transcatheter Aortic Valve Replacement (TAVR). Methods: Between March 2014 and June 2019, a total of 134 high-risk patients with pure, symptomatic severe AR patients were enrolled in the current study. The outcome was assessed according to the VARC-2 criteria. Procedural results, clinical outcomes, and the patients’ hemodynamics for a period of 1-year were analyzed. Results: Patient mean was 73.1±6.4 years and 25.4% were female. The average STS score was 9.8+5.3%. Procedural success was 97.1% (130/134), and the device success rate was 96.3% (129/134). Five cases were converted to open surgery, while two patients underwent valvular reinterventions (surgical aortic valve replacement for thrombosis and increasing paravalvular regurgitation). The mean aortic valve gradient was 10.2±4.1 mmHg, while the moderate and severe aortic regurgitation was 1.6% at 1 year. Paravalvular regurgitation was none/trivial in 79.8% and mild in 18.5%. The 1-year all-cause mortality rate was 7.4%. At 1-year, the stroke incidence rate was 2.2%. And pacemaker was implanted in 8.9% of the enrolled patients. Conclusions: In high-risk patients undergoing transapical-TAVR for AR, the use of the J-Valve is safe and effective TAVR should be considered as a reasonable option for high-risk patients with pure AR.

scholarly journals Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients

Circulation ◽  
2018 ◽  
Vol 138 (23) ◽  
pp. 2597-2607 ◽  
Author(s):  
Romain Didier ◽  
Hélène Eltchaninoff ◽  
Patrick Donzeau-Gouge ◽  
Karine Chevreul ◽  
Jean Fajadet ◽  
...  
Keyword(s):  
High Risk ◽  
Aortic Valve ◽  
Clinical Outcome ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
High Risk Patients ◽  
Transcatheter Aortic Valve ◽  
Risk Patients
Sign in / Sign up

Export Citation Format

Share Document